The differentiation of patient-derived induced pluripotent stem cells (iPSCs) to committed fates such as neurons, muscle and liver is a powerful approach for understanding key parameters of human development and disease [1] [2] [3] [4] [5] [6] . Whether undifferentiated iPSCs themselves can be used to probe disease mechanisms is uncertain. Dyskeratosis congenita is characterized by defective maintenance of blood, pulmonary tissue and epidermal tissues and is caused by mutations in genes controlling telomere homeostasis 7, 8 . Short telomeres, a hallmark of dyskeratosis congenita, impair tissue stem cell function in mouse models, indicating that a tissue stem cell defect may underlie the pathophysiology of dyskeratosis congenita 9, 10 . Here we show that even in the undifferentiated state, iPSCs from dyskeratosis congenita patients harbour the precise biochemical defects characteristic of each form of the disease and that the magnitude of the telomere maintenance defect in iPSCs correlates with clinical severity. In iPSCs from patients with heterozygous mutations in TERT, the telomerase reverse transcriptase, a 50% reduction in telomerase levels blunts the natural telomere elongation that accompanies reprogramming. In contrast, mutation of dyskerin (DKC1) in X-linked dyskeratosis congenita severely impairs telomerase activity by blocking telomerase assembly and disrupts telomere elongation during reprogramming. In iPSCs from a form of dyskeratosis congenita caused by mutations in TCAB1 (also known as WRAP53), telomerase catalytic activity is unperturbed, yet the ability of telomerase to lengthen telomeres is abrogated, because telomerase mislocalizes from Cajal bodies to nucleoli within the iPSCs. Extended culture of DKC1-mutant iPSCs leads to progressive telomere shortening and eventual loss of self-renewal, indicating that a similar process occurs in tissue stem cells in dyskeratosis congenita patients. These findings in iPSCs from dyskeratosis congenita patients reveal that undifferentiated iPSCs accurately recapitulate features of a human stem cell disease and may serve as a cell-culturebased system for the development of targeted therapeutics.
Patients with dyskeratosis congenita have high rates of bone marrow failure, pulmonary fibrosis and cancer, and a triad of epidermal findings, including oral leukoplakia, nail dystrophy and abnormal skin pigmentation 7, 11 . The severity of dyskeratosis congenita and its age of onset vary widely; the reason for this range of phenotypes is unclear, but it depends in part on the mode of inheritance and the specific genes involved. Patients with X-linked dyskeratosis congenita due to mutations in DKC1 typically present in early childhood with the classic manifestations of the disease 11, 12 . In contrast, autosomal dominant dyskeratosis congenita due to mutations in TERT or TERC, the telomerase RNA component, presents in adolescence or young adulthood, and disease manifestations are often milder, with patients commonly lacking the epidermal triad. Patients with autosomal recessive dyskeratosis congenita due to TCAB1 mutations have the classic and severe form of the disease, with early age of onset and shortened life expectancy 13 . All forms of dyskeratosis congenita are associated with very short telomeres in peripheral blood lymphocytes 14 . Telomerase is restricted in its expression in many tissues to stem cells and progenitor cells, and the challenges in isolating and studying these rare cells have precluded a direct analysis of telomere maintenance mechanisms in stem cells from patients with dyskeratosis congenita. In skin fibroblasts, telomerase expression is silenced, but during reprogramming the TERT gene is reactivated and telomerase activity is reconstituted 1, [15] [16] [17] . Dyskeratosis congenita iPSCs have been used to study telomerase reactivation and TERC regulation during reprogramming, but thus far disease-specific iPSCs have not recapitulated telomere shortening 15 .
To study dyskeratosis congenita in patient-derived iPSCs, fibroblasts from five patients carrying different mutations in TERT (P704S and R979W), TCAB1 (H376Y/G435R) and DKC1 (L54V and DL37) were transduced with retroviruses or lentiviruses expressing the reprogramming factors SOX2, c-Myc (also known as MYC), KLF4 and OCT4 (Supplementary Tables 1 and 2 ). Dyskeratosis congenita fibroblasts were resistant to reprogramming in ambient oxygen, but successful reprogramming was achieved under low oxygen conditions (5% O 2 ), a method that mitigates cellular stress responses 18 ( Supplementary  Table 1 ). To generate isogenic iPSCs with the DKC1(DL37) mutation but with long telomeres, we reprogrammed DKC1(DL37) fibroblasts in which TERT and TERC were stably overexpressed (TT), which bypasses the effects of the dyskerin mutation 19 (DKC1(DL37/TT) iPSCs). The resulting iPSCs from dyskeratosis congenita patients were morphologically indistinguishable from human embryonic stem (ES) cells, were positive for all markers of pluripotency tested and gave rise to cells derived from all three germ layers ( Supplementary Figs 1-6 ).
Both autosomal dominant TERT-mutation-positive patients presented with bone marrow failure and short telomeres, but lacked the epidermal triad ( Fig. 1a , Supplementary Fig. 7a and Supplementary  Table 2 ). To assess the effects of the mutations on telomerase catalytic activity, wild-type or mutant TERT proteins were assembled into telomerase in human 293T cells. Following immunopurification, telomerase activity of each reconstituted enzyme was analysed using a quantitative direct enzymatic assay ( Fig. 1b ). For each mutant TERT, the enzymatic activity of reconstituted telomerase was reduced by 90%, and the defect was not suppressed by the telomere-binding proteins POT1 and TPP1, which enhance telomerase processivity 20 ( Supplementary  Fig. 8 ). In the iPSCs derived from these patients, TERT messenger RNA and TERC were upregulated similarly compared with wild-type iPSCs by polymerase chain reaction with reverse transcription (RT-PCR) and northern blot, respectively ( Fig. 1c ). Both dyskerin and TCAB1 were strongly upregulated by western blot with reprogramming ( Fig. 1c ). Telomerase activity in both TERT-mutant iPSCs was reduced by approximately 50% compared to wild-type iPSCs, consistent with our findings that each mutant TERT protein retains only 10% residual activity, which when added to the activity from the wild-type allele would be predicted to yield 55% total activity in a heterozygote ( Fig. 1d ). Thus, our findings in TERT-mutant iPSCs are compatible with a mechanism of telomerase haploinsufficiency, whereby a 50% reduction in activity is the cause of disease in this form of dyskeratosis congenita 21, 22 .
The patient with compound heterozygous mutations in TCAB1 presented with classical symptoms of dyskeratosis congenita, including very short telomeres ( Fig. 1a, Supplementary Fig. 7b and Supplementary Table 2 ). TERT, TERC and dyskerin were each appropriately upregulated in TCAB1-mutant iPSCs, whereas TCAB1 protein levels were markedly reduced ( Fig. 2a) 13 . Although patients with mutations in TCAB1 have short telomeres, telomerase activity was unperturbed by TCAB1 mutations and indistinguishable from activity in wildtype iPSCs (Fig. 2b ). TCAB1 is enriched in Cajal bodies, nuclear sites of ribonucleoprotein modification and assembly, and is required for trafficking of telomerase to Cajal bodies 23, 24 . Whereas TCAB1 colocalized in discrete foci with the Cajal-body marker p80-coilin in wildtype iPSCs, TCAB1-mutant iPSCs showed a marked reduction of TCAB1 accumulation in Cajal bodies ( Fig. 2c and Supplementary  Fig. 9a ; P , 0.0001). Dyskerin normally accumulates both in Cajal bodies, where it binds small Cajal-body-specific RNAs (scaRNAs) and TERC, and in the nucleolus, where it binds small nucleolar RNAs (snoRNAs) that possess an H/ACA sequence motif. Efficient accumulation of dyskerin in Cajal bodies requires functional TCAB1 (ref. 13 ). TCAB1-mutant iPSCs showed a significant reduction in dyskerin accumulation in Cajal bodies, whereas nucleolar localization of dyskerin was unperturbed ( Fig. 2d and Supplementary Fig. 9b ; P , 0.0001). RNA fluorescent in situ hybridization (FISH) revealed that, whereas TERC localized to a single Cajal body focus in wild-type iPSCs, it showed marked mislocalization to nucleoli in TCAB1-mutant iPSCs ( Fig. 2e and Supplementary Figs 9c and 10; P , 0.0001). Together, these data show that TCAB1 mutations in patient-derived iPSCs result in mislocalization of the telomerase complex without affecting telomerase activity. Our findings indicate that simple catalytic assays can falsely suggest that telomerase is active in a setting in which the telomerase enzyme is profoundly dysfunctional, results reminiscent of the first telomerase mutations in yeast 25 .
Patients with X-linked dyskeratosis congenita included one with classic dyskeratosis congenita due to the DKC1(DL37) mutation 12, 15 and another who presented with bone marrow failure, the epidermal triad and very short telomeres due to a DKC1(L54V) mutation ( Fig. 1a , Supplementary Fig. 7c and Supplementary Table 2 ). TERT mRNA, dyskerin protein and TCAB1 protein were upregulated appropriately after cellular reprogramming in DKC1-mutant iPSCs (Fig. 3a ). Dyskerin 
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serves a central role in assembling telomerase and other ribonucleoprotein complexes with RNAs containing H/ACA motifs 12, 26 . The H/ACA motif within TERC is shared with scaRNAs and a subset of snoRNAs, involved in modification of splicing RNAs and ribosomal RNAs, respectively 26 . TERC was reduced in DKC1-mutant fibroblasts by northern blot, consistent with previous studies 12 (Fig. 3a) . Despite an upregulation of TERC with reprogramming, TERC in DKC1-mutant iPSCs remained significantly suppressed compared with wild-type iPSC controls. DKC1 point mutations selectively reduced TERC levels without affecting H/ACA snoRNAs and scaRNAs, recapitulating results in lymphoblasts and fibroblasts 12 (Supplementary Fig. 11 ). In marked contrast to TERT-mutant and TCAB1-mutant iPSCs, all DKC1-mutant iPSC clones exhibited a severe reduction of telomerase activity, ranging from 5-15% of wild-type controls (Fig. 3b, c and Supplementary Fig. 12 ). Overexpression of TERT and TERC restored TERC levels by northern blot and rescued telomerase activity in DKC1(DL37/TT) fibroblasts and DKC1(DL37/TT) iPSCs by TRAP ( Supplementary Fig. 12 ).
To assess the composition of the fully assembled telomerase holoenzyme in DKC1-mutant iPSCs, dyskerin and TCAB1 were immunoprecipitated from whole-cell extracts using antibodies directed against each protein. TERC was readily detected by northern blot in dyskerin and TCAB1 complexes from wild-type iPSCs. In contrast, the amount of TERC assembled with either dyskerin or TCAB1 was markedly reduced in DKC1(DL37) iPSCs ( Fig. 3d and Supplementary Fig. 13 ).
Overexpression of TERT and TERC in DKC1(DL37/TT) iPSCs rescued the assembly defect and led to an amount of TERC in the mature holoenzyme that exceeded wild-type levels. Overall the amount of TERC in dyskerin and TCAB1 complexes in DKC1-mutant, wildtype and DKC1(DL37/TT) iPSCs correlated directly with telomerase enzymatic activity in X-linked dyskeratosis congenita iPSCs. Thus, the reduction in both TERC and telomerase activity in DKC1-mutant iPSCs is consistent with a defect in a dyskerin-mediated assembly step, impairing the maturation of the active telomerase complex.
Upregulation of telomerase leads to significant telomere lengthening during reprogramming of wild-type fibroblasts 1, 15, 16 (Fig. 4a-d) . However, in TERT-mutant iPSCs, telomere elongation during reprogramming was blunted, with telomeres in TERT-mutant iPSCs always remaining significantly shorter than in wild-type iPSCs ( Fig. 4a and Supplementary Fig. 14) . In marked contrast, telomere elongation failed in all TCAB1-mutant iPSCs and DKC1-mutant iPSCS. For both TCAB1-mutant iPSCs and DKC1-mutant iPSCs, telomeres were shorter than in their parental fibroblasts and telomeres continued to shorten as cells divided in culture (Fig. 4b-d and Supplementary Figs 14  and 15 ). In DKC1(DL37/TT) fibroblasts and iPSCs, telomerase overexpression fully restored telomere elongation, with telomere lengths increasing significantly beyond those of their wild-type counterparts (Fig. 4d) . These data show that telomerase mutations can severely impair telomere maintenance in dyskeratosis congenita iPSCs, providing evidence for a defect in maintaining telomeres in dyskeratosis congenita stem cells.
With extended proliferation in cell culture of DKC1(DL37) iPSCs, telomeres continued to shorten through passage 19 and the bulk population of telomeres reached a plateau at passage 26 by Southern blot ( Supplementary Fig. 15b ). Using telomere FISH, we found that telomere signals were readily detected at all chromosome ends in wild-type iPSCs and in DKC1(DL37/TT) iPSCs. In contrast, average telomere intensity was greatly reduced in DKC1(DL37) iPSCs, which also showed an increase in the number of signal-free ends (SFEs), chromosome ends lacking detectable telomere repeats ( Fig. 4e-h ; P , 0.01). Continued passage of DKC1(DL37) iPSCs resulted in an abrupt increase in spontaneous differentiation within iPSC colonies and the culture could no longer be maintained as undifferentiated iPSCs after passage 36. Critical telomere shortening leads to a loss of telomere capping function, which triggers a DNA damage response that activates the p53 tumour suppressor protein. The p53 pathway was strongly activated in DKC1(DL37) iPSCs at passage 36, as evidenced by p53 protein stabilization and induction of its downstream target p21 by western blot. No such activation of p53 was seen at passage 9, or in late-passage human ES cells (Fig. 4i ). Taken together, these data show that impaired telomere maintenance in dyskeratosis congenita iPSCs can ultimately compromise self-renewal, resulting in a finite cellular lifespan.
Our data in patient-derived iPSCs provide evidence for severe defects in telomerase function and telomere maintenance in stem cells from dyskeratosis congenita patients. The spontaneous differentiation in DKC1-mutant iPSCs indicates that exhaustion of self-renewal in haematopoietic stem cells and other tissue stem cells may underlie the tissue defect in dyskeratosis congenita. Restoration of telomerase function through pharmacological or genetic means in stem cells from blood, lung or epidermal tissues may therefore provide a rational guide for therapy of dyskeratosis congenita. Data from these iPSCs provide an explanation for the long-standing clinical observation that X-linked dyskeratosis congenita is often more severe and presents at a younger age than autosomal dominant dyskeratosis congenita caused by mutations in TERT or TERC 8 . Our data indicate that effective telomerase activities in the 15-50% range may represent a critical threshold in which telomere maintenance is particularly impaired. Thus, a reduction in telomerase activity to the 15-50% range may be necessary to yield severe phenotypes in a single generation, whereas genetic anticipation 21, 22 through inheritance of heterozygous mutations in TERT for several generations may be important in eliciting disease phenotypes for autosomal dominant patients with greater than 50% residual telomerase activity. Together, our data show that many important features of a human stem cell disease are accurately recapitulated in patient-derived iPSCs, providing an iPSCbased system that is not dependent upon differentiation to probe disease mechanisms or to identify potential therapeutics. Filled black square in a, membrane cut for hybridization. e-h, Telomere FISH on metaphase chromosomes from wild-type iPSCs (e), DKC1(DL37) iPSC clone 1 (f) and DKC1(DL37/TT) (g) iPSCs at passage 22. White arrows, SFEs. High magnification, inset. h, Quantification of SFEs per metaphase. i, Western blot for p53 and p21 at passage 9 and passage 36 in DKC1(DL37) iPSCs. DOX, doxorubicin treated. Tubulin, loading control.

